

AllerGen Clinical Investigator Collaborative Fact Sheet

AllerGen NCE Inc. (AllerGen), a Federal Network of Centres of Excellence, has developed the Clinical Investigator Collaborative (CIC) as an efficient, cost-effective solution to fast-track new therapeutic entities in allergy and asthma, and to enhance knowledge about their mechanisms of action and clinical efficacy.

The AllerGen CIC is a unique clinical trials consortium established to:

- Fast-track early-stage potential drug candidates for allergic rhinitis and asthma
- Study the pathobiology of allergic rhinitis and asthma
- Discover new drugs for allergic rhinitis and asthma

Innovation and Added Value


- Mechanistic therapeutic studies
- Secondary prevention studies (eg. antileukotrienes)
- Studies to develop, characterize and/or optimize clinical models
- Development of new concepts and translational research through collaborative work and interaction

Impact

- Fast-tracks new therapeutic entities in allergy and asthma and enhances knowledge about their mechanisms of action and clinical efficacy
- Uses studies to understand mechanisms
- Provides training in methods used to evaluate airway inflammation, clinical research and pharmacology
- Is standardizing methodologies across Canada

Current Clients: **IVAX Research Inc., TOPIGEN Pharmaceuticals, Boehringer Ingelheim, MedImmune Inc., Wyeth, Alexion Pharmaceuticals, Genentech, Schering**

National Network of Research Centres: **McMaster University, Laval University, University of Alberta, University of Saskatchewan, University of British Columbia**



AllerGen supports allergic and immune disease research with the potential to significantly improve the health of Canadians and generate economic benefits. The Network's research is undertaken by interdisciplinary teams in partnership with industry, not-for-profit, public policy and healthcare organizations. AllerGen is a member of the Networks of Centres of Excellence (NCE) program, a joint initiative of the Canadian Institutes of Health Research, the Natural Sciences and Engineering Research Council, the Social Sciences and Humanities Research Council and Industry Canada. www.allergen-nce.ca

For more information, contact:

Dr. Paul O'Byrne, E.J. Moran Campbell Professor of Medicine, Chair, Department of Medicine, McMaster University, 905-521-2100 ext 76373, obyrne@mcmaster.ca, or

Dr. Diana Royce, AllerGen Managing Director, 905-525-9140 ext 26502, deerfieldgroup@sympatico.ca

AllerGen NCE Inc. Michael DeGroot Centre for Learning and Discovery – Room 3120, McMaster University
1200 Main Street West, Hamilton, ON, L8N 3Z5

Innovation from Cell to Society